Escalating dosing regimen for effecting weight loss and treating obesity
The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions.
1. A method for effecting weight loss in a patient having a body mass index of at least 25 kg/m 2 , comprising administering an escalating unit dosage form comprising,
(a) a first dosage form, comprising,
23 mg of topiramate, formulated for controlled release, and
3.75 mg of phentermine, formulated for immediate release,
wherein the first dosage form is administered to the subject daily for at least 2 weeks; and
(b) a second dosage form, comprising,
46 mg of topiramate, formulated for controlled release, and
7.5 mg of phentermine, formulated for immediate release,
wherein the topiramate formulated for controlled release reaches maximum plasma concentration (Cmax) at about 6 to about 10 hours (Tmax) after administration.
2. The method of claim 1 , wherein the subject has a body mass index between 25 kg/m 2 and 29.9 kg/m 2 .
3. The method of claim 2 , wherein the subject has a condition associated with obesity.
4. The method of claim 1 , wherein the subject has a body mass index of at least 30 kg/m 2 .
5. The method of claim 3 , wherein the condition associated with obesity is selected from the group consisting of diabetes, elevated fasting blood glucose, insulin resistance, impaired glucose tolerance, pulmonary hypertension, asthma, shortness of breath, gallbladder disease, dyslipidemia, high cholesterol, high levels of triglycerides, osteoarthritis, reflux esophagitis, sleep apnea, menstrual irregularities, infertility, complications in pregnancy, gout, high blood pressure, hypertension, coronary artery disease, heart disease, muscular dystrophy, stroke, thrombotic stroke, deep vein thrombosis (DVT), migraines, metabolic disorders, hypoalphalipoproteinemia, familial combined hyperlipidemia, Syndrome X, insulin-resistant Syndrome X, colon cancer, rectal cancer, renal cancer, esophageal cancer, gallbladder cancer, pancreatic cancer, prostate cancer, breast cancer, uterine cancer, ovarian cancer, endometrial cancer, and cervical cancer.
6. The method of claim 3 , wherein the condition associated with obesity is selected from the group consisting of hypertension, dyslipidemia, and type 2 diabetes mellitus.
7. The method of claim 5 , wherein the condition associated with obesity is selected from the group consisting of high blood pressure, high levels of triglycerides, elevated fasting blood glucose, and diabetes.
8. The method of claim 3 , wherein the subject is suffering from at least two conditions associated with obesity selected from the group consisting of high blood pressure, high levels of triglycerides, elevated fasting blood glucose, and diabetes.
9. The method of claim 3 , wherein the subject is suffering from at least two conditions associated with obesity selected from the group consisting of hypertension, dyslipidemia, and type 2 diabetes mellitus.
10. The dosage form of claim 1 , wherein the topiramate formulated for controlled release further exhibits a lower Cmax, than non-controlled release topiramate, without decreasing total drug exposure defined by the area under the concentration-time curve (AUC).
11. The method of claim 1 , wherein the 3.75 mg phentermine is provided in the first dosage form as about 4.92 mg phentermine hydrochloride, and wherein 4.92 mg of phentermine hydrochloride provides 3.75 mg of phentermine.
12. The method of claim 1 , wherein the 7.5 mg phentermine is provided in the second dosage form as about 9.84 mg phentermine hydrochloride, and wherein 9.84 mg of phentermine hydrochloride provides 7.5 mg of phentermine.
13. The method of claim 1 , wherein the topiramate formulated for controlled release reaches maximum plasma concentration (Cmax) at a time (Tmax) that is delayed by about 6 to about 8 hours compared to the Tmax of non-controlled release topiramate and exhibits a lower Cmax than non-controlled release topiramate.
14. The method of claim 1 , wherein the topiramate formulated for controlled release is formulated for sustained release, delayed release, or both.
15. The method of claim 1 , wherein the escalating unit dosage form is formulated for oral administration.
16. The method of claim 1 , wherein the weight loss is effective to achieve a reduction of at least about 10% of body weight.
17. A method for effecting weight loss in a patient having a body mass index of at least 25 kg/m 2 , comprising administering an escalating unit dosage form comprising,
(a) a first dosage form, comprising,
23 mg of topiramate, formulated for controlled release, and
3.75 mg of phentermine, formulated for immediate release,
wherein the first dosage form is administered to the subject daily for at least 2 weeks; and
(b) a second dosage form, comprising,
92 mg of topiramate, formulated for controlled release, and
15 mg of phentermine, formulated for immediate release,
wherein the topiramate formulated for controlled release reaches maximum plasma concentration (Cmax) at about 6 to about 10 hours (Tmax) after administration.
18. The method of claim 17 , wherein the subject has a body mass index between 25 kg/m 2 and 29.9 kg/m 2 .
19. The method of claim 18 , wherein the subject has a condition associated with obesity.
20. The method of claim 17 , wherein the subject has a body mass index of at least 30 kg/m 2 .
21. The method of claim 19 , wherein the condition associated with obesity is selected from the group consisting of diabetes, elevated fasting blood glucose, insulin resistance, impaired glucose tolerance, pulmonary hypertension, asthma, shortness of breath, gallbladder disease, dyslipidemia, high cholesterol, high levels of triglycerides, osteoarthritis, reflux esophagitis, sleep apnea, menstrual irregularities, infertility, complications in pregnancy, gout, high blood pressure, hypertension, coronary artery disease, heart disease, muscular dystrophy, stroke, thrombotic stroke, deep vein thrombosis (DVT), migraines, metabolic disorders, hypoalphalipoproteinemia, familial combined hyperlipidemia, Syndrome X, insulin-resistant Syndrome X, colon cancer, rectal cancer, renal cancer, esophageal cancer, gallbladder cancer, pancreatic cancer, prostate cancer, breast cancer, uterine cancer, ovarian cancer, endometrial cancer, and cervical cancer.
22. The method of claim 19 , wherein the condition associated with obesity is selected from the group consisting of hypertension, dyslipidemia, and type 2 diabetes mellitus.
23. The method of claim 21 , wherein the condition associated with obesity is selected from the group consisting of high blood pressure, high levels of triglycerides, elevated fasting blood glucose, and diabetes.
24. The method of claim 19 , wherein the subject is suffering from at least two conditions associated with obesity selected from the group consisting of high blood pressure, high levels of triglycerides, elevated fasting blood glucose, and diabetes.
25. The method of claim 19 , wherein the subject is suffering from at least two conditions associated with obesity selected from the group consisting of hypertension, dyslipidemia, and type 2 diabetes mellitus.
26. The dosage form of claim 17 , wherein the topiramate formulated for controlled release further exhibits a lower Cmax, than non-controlled release topiramate, without decreasing total drug exposure defined by the area under the concentration-time curve (AUC).
27. The method of claim 17 , wherein the 3.75 mg phentermine is provided in the first dosage form as about 4.92 mg phentermine hydrochloride, and wherein 4.92 mg of phentermine hydrochloride provides 3.75 mg of phentermine.
28. The method of claim 17 , wherein the topiramate formulated for controlled release reaches maximum plasma concentration (Cmax) at a time (Tmax) that is delayed by about 6 to about 8 hours compared to the Tmax of non-controlled release topiramate and exhibits a lower Cmax than non-controlled release topiramate.
29. The method of claim 17 , wherein the topiramate formulated for controlled release is formulated for sustained release, delayed release, or both.
30. The method of claim 17 , wherein the escalating unit dosage form is formulated for oral administration.
31. The method of claim 17 , wherein the weight loss is effective to achieve a reduction of at least about 10% of body weight.